Logo image of CTXR

CITIUS PHARMACEUTICALS INC (CTXR) Stock Fundamental Analysis

NASDAQ:CTXR - Nasdaq - US17322U3068 - Common Stock - Currency: USD

0.7325  +0.01 (+1.74%)

Fundamental Rating

2

Overall CTXR gets a fundamental rating of 2 out of 10. We evaluated CTXR against 198 industry peers in the Pharmaceuticals industry. While CTXR seems to be doing ok healthwise, there are quite some concerns on its profitability. CTXR has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CTXR has reported negative net income.
CTXR had a negative operating cash flow in the past year.
In the past 5 years CTXR always reported negative net income.
CTXR had a negative operating cash flow in each of the past 5 years.
CTXR Yearly Net Income VS EBIT VS OCF VS FCFCTXR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

CTXR's Return On Assets of -33.74% is in line compared to the rest of the industry. CTXR outperforms 48.48% of its industry peers.
Looking at the Return On Equity, with a value of -62.26%, CTXR is in line with its industry, outperforming 51.01% of the companies in the same industry.
Industry RankSector Rank
ROA -33.74%
ROE -62.26%
ROIC N/A
ROA(3y)-32.16%
ROA(5y)-30.75%
ROE(3y)-42.39%
ROE(5y)-39.56%
ROIC(3y)N/A
ROIC(5y)N/A
CTXR Yearly ROA, ROE, ROICCTXR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CTXR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTXR Yearly Profit, Operating, Gross MarginsCTXR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for CTXR has been increased compared to 1 year ago.
CTXR has less shares outstanding than it did 5 years ago.
There is no outstanding debt for CTXR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CTXR Yearly Shares OutstandingCTXR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
CTXR Yearly Total Debt VS Total AssetsCTXR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

CTXR has an Altman-Z score of -3.80. This is a bad value and indicates that CTXR is not financially healthy and even has some risk of bankruptcy.
CTXR has a Altman-Z score of -3.80. This is comparable to the rest of the industry: CTXR outperforms 42.93% of its industry peers.
There is no outstanding debt for CTXR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.8
ROIC/WACCN/A
WACCN/A
CTXR Yearly LT Debt VS Equity VS FCFCTXR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 0.41 indicates that CTXR may have some problems paying its short term obligations.
With a Current ratio value of 0.41, CTXR is not doing good in the industry: 92.42% of the companies in the same industry are doing better.
A Quick Ratio of 0.09 indicates that CTXR may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.09, CTXR is doing worse than 95.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.41
Quick Ratio 0.09
CTXR Yearly Current Assets VS Current LiabilitesCTXR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CTXR have decreased strongly by -290.48% in the last year.
EPS 1Y (TTM)-290.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 26.08% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y84.48%
EPS Next 2Y57.32%
EPS Next 3Y41.71%
EPS Next 5Y26.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTXR Yearly Revenue VS EstimatesCTXR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
CTXR Yearly EPS VS EstimatesCTXR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

CTXR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 0.35, which indicates a rather cheap valuation of CTXR.
CTXR's Price/Forward Earnings ratio is rather cheap when compared to the industry. CTXR is cheaper than 100.00% of the companies in the same industry.
CTXR is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.85, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 0.35
CTXR Price Earnings VS Forward Price EarningsCTXR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTXR Per share dataCTXR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CTXR's earnings are expected to grow with 41.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.32%
EPS Next 3Y41.71%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CTXR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CITIUS PHARMACEUTICALS INC

NASDAQ:CTXR (5/23/2025, 9:30:58 AM)

0.7325

+0.01 (+1.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11
Inst Owners7.63%
Inst Owner Change-4.21%
Ins Owners5.74%
Ins Owner Change0%
Market Cap7.54M
Analysts82.22
Price Target7.14 (874.74%)
Short Float %7.19%
Short Ratio2.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-62.53%
Min EPS beat(2)-121.01%
Max EPS beat(2)-4.05%
EPS beat(4)1
Avg EPS beat(4)-31.1%
Min EPS beat(4)-121.01%
Max EPS beat(4)18.3%
EPS beat(8)1
Avg EPS beat(8)-83.11%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-17.65%
PT rev (3m)-17.65%
EPS NQ rev (1m)82.5%
EPS NQ rev (3m)88.33%
EPS NY rev (1m)63.19%
EPS NY rev (3m)63.59%
Revenue NQ rev (1m)50%
Revenue NQ rev (3m)-70.83%
Revenue NY rev (1m)11.92%
Revenue NY rev (3m)-60.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.35
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.12
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.66
EYN/A
EPS(NY)2.09
Fwd EY285.46%
FCF(TTM)-3.09
FCFYN/A
OCF(TTM)-2.6
OCFYN/A
SpS0
BVpS6.36
TBVpS-3.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.74%
ROE -62.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.16%
ROA(5y)-30.75%
ROE(3y)-42.39%
ROE(5y)-39.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.41
Quick Ratio 0.09
Altman-Z -3.8
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-290.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.6%
EPS Next Y84.48%
EPS Next 2Y57.32%
EPS Next 3Y41.71%
EPS Next 5Y26.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.09%
OCF growth 3YN/A
OCF growth 5YN/A